The Competition Commission of India has approved the proposed amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with Sequent Scientific Limited.

Sequent Scientific Limited (SSL) is a publicly listed company, having operations globally in the animal healthcare industry. The company offers a comprehensive range of Active Pharmaceutical Ingredients (APIs), finished dosage formulations (FDFs), and analytical services to meet the needs of the animal health sector. Sequent Research Limited (SRL) is a wholly owned subsidiary of SSL, which operates as a Contract Research Organization providing analytical services and a wide array of testing to the global pharmaceutical industry.

Viyash Life Sciences Private Limited (Viyash) is a pharmaceutical company and through its subsidiaries is primarily engaged in the development, manufacture and sale of APIs and intermediates for human healthcare in India. Further, it also manufactures FDFs for human healthcare. Symed Labs Limited (Symed), Appcure Labs Private Limited (Appcure), Vindhya Pharma (India) Private Limited (Vindhya Pharma) and  Vandana Life Sciences Private Limited (Vandana) are wholly owned subsidiaries of Viyash and S.V. Labs Private Limited (SV Labs) is a wholly owned step-down subsidiary of Viyash (through Vindhya Pharma)

Geninn Life Sciences Private Limited (Geninn) is a holding company and does not have any operations of its own. It has a wholly owned subsidiary, Vindhya Organics Private Limited (Vindhya Organics) which is primarily engaged in the business of development, manufacture and marketing APIs for human healthcare.

The Proposed Combination involves a series of inter-connected steps carried out for the amalgamation of SRL, Viyash, Symed, Appcure, Vindhya Pharma, Vandana, Vindhya Organics, Geninn and SV Labs with SSL as the ultimate surviving entity (Proposed Combination).

Detailed order of the Commission will follow.

Amalgamation approval confirms consolidation of multiple pharmaceutical entities into a single surviving animal health company after regulatory review. The Competition Commission approved the proposed amalgamation of Sequent Research Limited, Viyash Life Sciences and its group companies, Geninn Life Sciences and Vindhya Organics with Sequent Scientific Limited as the ultimate surviving entity. The parties' principal activities are identified (SSL in animal healthcare with APIs, FDFs and analytical services; SRL as a contract research/analytical subsidiary; Viyash group in APIs and FDFs for human healthcare; Geninn as a holding company). The combination is effected through a series of interconnected amalgamation steps and a detailed Commission order will follow.